Trial Profile
A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adrenal cancer; Bladder cancer; Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- 04 Jun 2023 Planned primary completion date changed from 17 Oct 2022 to 17 Oct 2023.
- 07 Jun 2022 Results (n=10) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 26 Apr 2022 Status changed from not yet recruiting to recruiting.